How Does EBV Cause Lymphoma in CHH?
At a Glance
In Cartilage-Hair Hypoplasia (CHH), weakened T-cells struggle to control the Epstein-Barr virus (EBV). This allows infected cells to multiply uncontrollably, significantly increasing the risk of blood cancers like lymphoma. Regular cancer screening and viral monitoring are essential for patients.
In this answer
4 sections
Learning about cancer risks associated with a chronic condition can be frightening, but understanding the biological “why” behind your doctor’s warnings empowers you to stay safely monitored. In people with Cartilage-Hair Hypoplasia (CHH), catching the Epstein-Barr Virus (EBV)—the common virus that causes infectious mononucleosis (“mono”)—requires careful medical monitoring because the immune system struggles to keep the virus in check. Normally, specialized immune cells called T-cells act as security guards that find and destroy cells infected by EBV. However, CHH weakens the T-cell response. Without enough active T-cells to clear the virus, EBV can force infected cells to multiply uncontrollably. Over time, this runaway cell division can lead to lymphoproliferative disorders and eventually drive the development of blood cancers like lymphoma [1][2].
How the Immune System Usually Handles EBV
Epstein-Barr Virus is incredibly common; most people catch it at some point in their lives. When the virus enters the body, it primarily targets and infects B-cells, another type of white blood cell.
In a person with a typical immune system, cytotoxic T-cells (T-cells designed to kill infected cells) quickly spot these infected B-cells and destroy them [2][3]. After the initial infection clears, the virus remains asleep (dormant) in the body forever, kept completely in check by a constant patrol of T-cells [4].
Why CHH Changes the Equation
CHH is caused by mutations in a gene called RMRP, which plays a critical role in how cells grow and divide [5][6]. This mutation uniquely impacts the immune system by:
- Impairing T-cell growth: T-cells in individuals with CHH have difficulty multiplying and activating when faced with a threat [5][6].
- Shortening cell lifespans: The immune cells in CHH patients often have shorter telomeres (the protective caps on the ends of DNA), which causes them to age faster and become exhausted [7][8].
Because of these defects, the T-cells are too weak or too few in number to effectively patrol and destroy the EBV-infected B-cells [7][2].
From Viral Infection to Lymphoma
When T-cells fail to kill the infected B-cells, EBV essentially hijacks the B-cells. The virus produces specific proteins that act like a stuck accelerator pedal, forcing the B-cells to survive longer than they should and multiply continuously [9][10].
This uncontrolled multiplication of cells is called a lymphoproliferative disorder [2]. As these B-cells divide rapidly and endlessly without immune pressure, they are highly prone to accumulating new genetic mistakes or mutations [11][12]. Eventually, these combined genetic errors can transform the proliferating cells into full-blown cancer, most commonly Diffuse Large B-cell Lymphoma (DLBCL) [13][11].
Patients with CHH have a notably increased risk for these EBV-associated lymphomas. Historically, these lymphomas have sometimes been diagnosed at an advanced stage [13][14]. This is exactly why proactive, regular screening is so critical—to catch any changes early before they become advanced.
What This Means for Your Care
Because the link between EBV and lymphoma in CHH is well-established, there are several concrete steps you and your doctor should take.
1. EBV Testing and Management
You should know your EBV status. Your doctor can run a simple blood test to see if you have already had EBV (meaning it is dormant in your body) or if you have never been exposed.
- If you are exposed to someone with mono: Contact your care team so they can decide if you need closer monitoring or preventative measures.
- Monitoring active virus: If you do develop an active EBV infection, your doctor can measure the “viral load” in your blood through standard lab tests to track how well your body is fighting it off [15].
2. Regular Cancer Screening
All individuals with CHH should receive regular screening for malignancies, regardless of whether they have felt sick [13][15]. This typically involves:
- Physical exams where your doctor checks for swollen lymph nodes in your neck, armpits, and groin.
- Routine blood tests to monitor your complete blood count (CBC) and check for markers of cell breakdown.
- Imaging scans (like ultrasounds or CT scans) if there are any suspicious symptoms or changes in your blood work.
3. Immune Monitoring
Doctors will frequently check how severely your immune system is impacted [15]. A common way to do this is a TRECs test (T-cell receptor excision circles), which is simply a standard blood draw that measures how many new, healthy T-cells your body is producing [16].
4. Watchful Waiting for “B Symptoms”
Patients and their families should be vigilant for a specific group of warning signs that doctors refer to as “B symptoms.” These include:
- Unexplained weight loss
- Drenching night sweats
- Prolonged, unexplained fevers
- Persistent swollen lymph nodes
If you notice any of these, contact your doctor right away.
5. Treatment Options Are Available
If EBV does cause complications or lymphoproliferation occurs, it is important to know that medical treatments exist. Depending on the severity, doctors may use targeted immune therapies, antivirals, or even consider a Hematopoietic Stem Cell Transplant (bone marrow transplant) to replace the defective immune system with a healthy one [17][18][19].
Common questions in this guide
Why does Cartilage-Hair Hypoplasia increase the risk of lymphoma?
What are the warning signs of lymphoma I should watch for?
How can my doctor monitor my Epstein-Barr virus status?
What is a TRECs test and why is it used?
Questions for Your Doctor
4 questions
- •What is my current EBV status, and should we be monitoring my EBV viral load with regular blood tests?
- •How often should I come in for physical exams and blood work to screen for lymphoma, and what specific markers will you be looking for?
- •Can you explain what a TRECs test might show about my specific T-cell function, and is this a test we should run?
- •If I or a family member develops symptoms of mononucleosis, what is our immediate action plan?
Questions for You
3 questions
- •Have I been experiencing any 'B symptoms' lately, such as unexplained weight loss, night sweats, or lingering fevers?
- •Do I know if I have ever been infected with the Epstein-Barr Virus in the past?
- •When was my last comprehensive physical exam that included checking my lymph nodes?
References
References (19)
- 1
The Finnish founder mutation c.70 A>G in RMRP causes cartilage-hair hypoplasia in a Pakistani family.
Iqbal M, Muhammad N, Ali SA, et al.
Clinical dysmorphology 2017; (26(2)):121-123 doi:10.1097/MCD.0000000000000155.
PMID: 27740950 - 2
Cytokine Storm Syndromes Associated with Epstein-Barr Virus.
Verbist K, Nichols KE
Advances in experimental medicine and biology 2024; (1448()):227-248 doi:10.1007/978-3-031-59815-9_16.
PMID: 39117818 - 3
Post-transplant lymphoproliferative disorder with cutaneous involvement: A series of four cases.
Ferreira MCC, Arai Seque C, Enokihara MMSES, et al.
Clinical transplantation 2021; (35(2)):e14162 doi:10.1111/ctr.14162.
PMID: 33217057 - 4
Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation.
Hoshino A, Takashima T, Yoshida K, et al.
The Journal of infectious diseases 2018; (218(5)):825-834 doi:10.1093/infdis/jiy231.
PMID: 29684201 - 5
A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis.
Robertson N, Shchepachev V, Wright D, et al.
Nature communications 2022; (13(1)):649 doi:10.1038/s41467-022-28295-8.
PMID: 35115551 - 6
The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
Vakkilainen S, Skoog T, Einarsdottir E, et al.
Scientific reports 2019; (9(1)):13758 doi:10.1038/s41598-019-50334-6.
PMID: 31551465 - 7
Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia.
Aubert G, Strauss KA, Lansdorp PM, Rider NL
The Journal of allergy and clinical immunology 2017; (140(4)):1120-1129.e1 doi:10.1016/j.jaci.2016.11.051.
PMID: 28126377 - 8
Decreased telomere length in children with cartilage-hair hypoplasia.
Kostjukovits S, Degerman S, Pekkinen M, et al.
Journal of medical genetics 2017; (54(5)):365-370 doi:10.1136/jmedgenet-2016-104279.
PMID: 27986801 - 9
Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in spontaneous lymphoblastoid cell lines.
Tam KP, Xie J, Au-Yeung RKH, Chiang AKS
PLoS pathogens 2024; (20(9)):e1012250 doi:10.1371/journal.ppat.1012250.
PMID: 39325843 - 10
EBV and Lymphomagenesis.
Sausen DG, Basith A, Muqeemuddin S
Cancers 2023; (15(7)) doi:10.3390/cancers15072133.
PMID: 37046794 - 11
Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
Marjanska A, Styczynski J
Expert opinion on biological therapy 2023; (23(6)):539-552 doi:10.1080/14712598.2023.2196366.
PMID: 36971380 - 12
EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.
Wilson JB, Manet E, Gruffat H, et al.
Cancers 2018; (10(4)) doi:10.3390/cancers10040109.
PMID: 29642420 - 13
Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
Kukkola HL, Utriainen P, Huttunen P, et al.
Frontiers in immunology 2022; (13()):1004694 doi:10.3389/fimmu.2022.1004694.
PMID: 36211439 - 14
Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis.
Sathishkumar D, Gach JE, Ogboli M, et al.
Clinical and experimental dermatology 2018; (43(6)):713-717 doi:10.1111/ced.13543.
PMID: 29744913 - 15
A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
Vakkilainen S, Taskinen M, Klemetti P, et al.
Frontiers in immunology 2019; (10()):1581 doi:10.3389/fimmu.2019.01581.
PMID: 31379817 - 16
Abnormal Newborn Screening Follow-up for Severe Combined Immunodeficiency in an Amish Cohort with Cartilage-Hair Hypoplasia.
Scott EM, Chandra S, Li J, et al.
Journal of clinical immunology 2020; (40(2)):321-328 doi:10.1007/s10875-019-00739-9.
PMID: 31903518 - 17
[Cartilage-hair hypoplasia. A case report].
Staines-Boones TA, González-Villarreal MG, Hernández-Fernández C
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2019; (66(3)):379-383 doi:10.29262/ram.v66i3.561.
PMID: 31606024 - 18
Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management.
Vakkilainen S, Taskinen M, Mäkitie O
Scandinavian journal of immunology 2020; (92(4)):e12913 doi:10.1111/sji.12913.
PMID: 32506568 - 19
Refractory/Relapsed Hodgkin Lymphoma in Cartilage Hair Hypoplasia-Anauxetic Dysplasia Spectrum: Long-term HSCT-free Remission in 2 Pediatric Siblings.
Bukhari SI, Yazdani S, Fadoo Z
Journal of pediatric hematology/oncology 2026; (48(2)):e91-e96 doi:10.1097/MPH.0000000000003158.
PMID: 41460196
This page is for educational purposes only and does not replace professional medical advice. Always consult your immunologist or oncologist about your specific lymphoma risk and screening plan.
Get notified when new evidence is published on Cartilage-hair hypoplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.